@article {R{\'a}k{\'o}czie000484, author = {{\'E}va R{\'a}k{\'o}czi and Zoltan Szekanecz}, title = {Pneumococcal vaccination in autoimmune rheumatic diseases}, volume = {3}, number = {2}, elocation-id = {e000484}, year = {2017}, doi = {10.1136/rmdopen-2017-000484}, publisher = {BMJ Specialist Journals}, abstract = {Streptococcus pneumoniae is the leading cause of the community-acquired pneumonia. The mortality rate of invasive pneumococcal infections is high. Immunocompromised patients suffering from autoimmune inflammatory rheumatic diseases (AIRD) have a high risk for acquiring these infections. Protection against infection can be improved with vaccination. After using polysaccharide vaccines (PPV-23), in July 2013, a 13-valent conjugate vaccine (PCV-13) was approved for adults. Due to its conjugate form, this vaccine is the recommended choice in pneumococcal vaccine-naive patients. PCV-13 is also recommended in patients previously receiving PPV-23. Vaccination in AIRD is very important and needs deliberate scheduling to coordinate with the immunosuppressive therapy. Here, based on international and national vaccine guidelines, we provide a current review of PPV-23 and PCV-13 vaccines for specialists following patients with AIRD.}, URL = {https://rmdopen.bmj.com/content/3/2/e000484}, eprint = {https://rmdopen.bmj.com/content/3/2/e000484.full.pdf}, journal = {RMD Open} }